Therefore, our study highlights safranal as a potential therapeutic agent for Pca recurrence and provides evidence that pharmacological inactivation of the NF-κB/E2F1–Skp2 axis is a potential therapeutic target against cancer recurrence and progression. The gene discussed is E2F1; the disease is cancer.